Naidoo P, Naidoo K, Karamchand S, Leisegang RF. Access to novel anti-diabetic agents in resource limited settings: A brief commentary. World J Diabetes 2023; 14(7): 939-941 [PMID: 37547585 DOI: 10.4239/wjd.v14.i7.939]
Corresponding Author of This Article
Poobalan Naidoo, BPharm, MBChB, MMedSc (Pharmacology), DipHIVMan (CMSA), Medical Registrar and Academic Research, Doctor, Department of Internal Medicine, Nelson R Mandela, School of Medicine, University of Kwa-Zulu Natal, Sydney Road, Umbilo, Durban 4001, Kwa-Zulu Natal, South Africa. poobalan1naidoo@yahoo.com
Research Domain of This Article
Medical Ethics
Article-Type of This Article
Opinion Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Jul 15, 2023; 14(7): 939-941 Published online Jul 15, 2023. doi: 10.4239/wjd.v14.i7.939
Access to novel anti-diabetic agents in resource limited settings: A brief commentary
Poobalan Naidoo, Kiolan Naidoo, Sumanth Karamchand, Rory F Leisegang
Poobalan Naidoo, Department of Internal Medicine, Nelson R Mandela, School of Medicine, University of Kwa-Zulu Natal, Durban 4001, Kwa-Zulu Natal, South Africa
Kiolan Naidoo, Department of Law, University of South Africa, Pretoria 3, Gauteng, South Africa
Sumanth Karamchand, Department of Cardiology, University of Stellenbosch and Tygerberg Hospital, Stellenbosch 7600, Western Cape, South Africa
Rory F Leisegang, Department of Pharmacometrics, Upsala University, Uppsala 751 04, Sweden
Author contributions: All authors contributed equally to this manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Poobalan Naidoo, BPharm, MBChB, MMedSc (Pharmacology), DipHIVMan (CMSA), Medical Registrar and Academic Research, Doctor, Department of Internal Medicine, Nelson R Mandela, School of Medicine, University of Kwa-Zulu Natal, Sydney Road, Umbilo, Durban 4001, Kwa-Zulu Natal, South Africa. poobalan1naidoo@yahoo.com
Received: October 13, 2022 Peer-review started: October 13, 2022 First decision: November 27, 2022 Revised: December 31, 2022 Accepted: June 13, 2023 Article in press: June 13, 2023 Published online: July 15, 2023
Abstract
The prevalence of diabetes mellitus is increasing in resource limited settings. Simultaneously, there has been an increase in the number of novel therapies for the management of diabetes mellitus. However, use of novel antidiabetic therapies is limited because of major market access challenges in resource limited settings. Niching products to those patients with the highest absolute risk for major adverse cardiovascular outcomes, and thus most likely to benefit from the therapy, are less likely to have negative budget impact for funders. To improve access, and reduce morbidity and mortality, requires alignment amongst key stakeholders including patient advocacy groups, health care professional councils, national departments of health, the pharmaceutical industry, treasury and finance departments.
Core Tip: The manuscript addresses the problem of access to novel anti-diabetic agents in resource limited settings. Niching therapies for use in those with highest major adverse cardiovascular risk, may limit budget impact for funders. To improve access, and reduce morbidity and mortality, requires alignment amongst key stakeholders including patient advocacy groups, health care professional councils, national departments of health, the pharmaceutical industry, treasury and finance departments.
